285 related articles for article (PubMed ID: 23587606)
21. Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.
Garbe E; Mikolajczyk RT; Banaschewski T; Petermann U; Petermann F; Kraut AA; Langner I
J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):452-8. PubMed ID: 23234588
[TBL] [Abstract][Full Text] [Related]
22. A 36 month naturalistic retrospective study of clinic-treated youth with attention-deficit/hyperactivity disorder.
Hong M; Lee WH; Moon DS; Lee SM; Chung US; Bahn GH
J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):341-6. PubMed ID: 24955936
[TBL] [Abstract][Full Text] [Related]
23. Comparison of prescription drug costs in the United States and the United Kingdom, part 3: methylphenidate.
Jick H; Wilson A; Wiggins P; Chamberlin DP
Pharmacotherapy; 2012 Nov; 32(11):970-3. PubMed ID: 23108719
[TBL] [Abstract][Full Text] [Related]
24. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
Foy JM; Earls MF
Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
[TBL] [Abstract][Full Text] [Related]
25. Overlapping Prescriptions of Stimulants for Children and Adolescents With Attention-Deficit Hyperactivity Disorder.
Chen CY; Yeh HH; Fang SY; Wu EC; Chang IS; Lin KM
Psychiatr Serv; 2012 Oct; 63(10):1011-8. PubMed ID: 22911441
[TBL] [Abstract][Full Text] [Related]
26. Naturalistic Pharmacotherapy Compliance among Pediatric Patients with Attention Deficit/Hyperactivity Disorder: a Study Based on Three-Year Nationwide Data.
Hong M; Kim B; Hwang JW; Bhang SY; Choi HY; Oh IH; Lee YJ; Bahn GH
J Korean Med Sci; 2016 Apr; 31(4):611-6. PubMed ID: 27051247
[TBL] [Abstract][Full Text] [Related]
27. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program.
Lawson KA; Johnsrud M; Hodgkins P; Sasané R; Crismon ML
Clin Ther; 2012 Apr; 34(4):944-956.e4. PubMed ID: 22444786
[TBL] [Abstract][Full Text] [Related]
28. Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?
Schawo S; van der Kolk A; Bouwmans C; Annemans L; Postma M; Buitelaar J; van Agthoven M; Hakkaart-van Roijen L
Pharmacoeconomics; 2015 May; 33(5):489-509. PubMed ID: 25715975
[TBL] [Abstract][Full Text] [Related]
29. [Sociodemographic and clinical factors associated with compliance to methylphenidate treatment in children with attention deficit hyperactivity disorder].
Kiliç BG; Bilgiç A; Gürkan K; Aysev A
Turk Psikiyatri Derg; 2007; 18(3):207-13. PubMed ID: 17853975
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder.
Donnelly M; Haby MM; Carter R; Andrews G; Vos T
Aust N Z J Psychiatry; 2004 Aug; 38(8):592-601. PubMed ID: 15298581
[TBL] [Abstract][Full Text] [Related]
31. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
[TBL] [Abstract][Full Text] [Related]
32. Early discontinuation of attention-deficit/hyperactivity disorder drug treatment: a Danish nationwide drug utilization study.
Pottegård A; Bjerregaard BK; Kortegaard LS; Zoëga H
Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):349-53. PubMed ID: 25220739
[TBL] [Abstract][Full Text] [Related]
33. Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan.
Wang LJ; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Shyu YC
Pharmacoepidemiol Drug Saf; 2016 Jan; 25(1):45-53. PubMed ID: 26549311
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
[TBL] [Abstract][Full Text] [Related]
35. Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder.
Aldridge AP; Kroutil LA; Cowell AJ; Reeves DB; Van Brunt DL
Pharmacoeconomics; 2011 Jul; 29(7):621-35. PubMed ID: 21473655
[TBL] [Abstract][Full Text] [Related]
36. Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder.
Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson TM; Xie J; Erder MH; Dammerman RS; Robertson B; Wu EQ
Am J Manag Care; 2014 Sep; 20(9):711-21. PubMed ID: 25365746
[TBL] [Abstract][Full Text] [Related]
37. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
38. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
Mikolajczyk R; Horn J; Schmedt N; Langner I; Lindemann C; Garbe E
JAMA Pediatr; 2015 Apr; 169(4):391-5. PubMed ID: 25686215
[TBL] [Abstract][Full Text] [Related]
39. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
[TBL] [Abstract][Full Text] [Related]
40. The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany.
Grimmsmann T; Himmel W
Eur J Clin Pharmacol; 2021 Jan; 77(1):107-115. PubMed ID: 32803292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
